Boston Scientific Corporation Stock
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.27 USD | -1.76% |
|
-18.45% | -20.01% |
| 02-06 | Markets Ask the Obvious Question |  |
| 02-06 | Analyst recommendations: Crown Holdings, Meta Platforms, Roku, Alphabet, Qualcomm… | |
| Capitalization | 113B 95.75B 87.9B 83.23B 155B 10,243B 161B 1,019B 404B 4,923B 424B 415B 17,824B | P/E ratio 2025 |
49.1x | P/E ratio 2026 * | 31x |
|---|---|---|---|---|---|
| Enterprise value | 122B 103B 94.76B 89.73B 167B 11,042B 174B 1,099B 435B 5,307B 457B 448B 19,215B | EV / Sales 2025 |
7.04x | EV / Sales 2026 * | 5.33x |
| Free-Float |
84.69% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Boston Scientific Corporation
| 1 day | -1.76% | ||
| 1 week | -18.45% | ||
| Current month | -18.45% | ||
| 1 month | -22.69% | ||
| 3 months | -23.75% | ||
| 6 months | -25.92% | ||
| Current year | -20.01% |
| 1 week | 74.86 |  | 94.18 |
| 1 month | 74.86 | | 99.09 |
| Current year | 74.86 | | 100.9 |
| 1 year | 74.86 | | 109.5 |
| 3 years | 45.92 | | 109.5 |
| 5 years | 34.98 | | 109.5 |
| 10 years | 16.25 | | 109.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 61 | 01/11/2011 |
Jonathan Monson
DFI | Director of Finance/CFO | 52 | 30/06/2025 |
John Sorenson
COO | Chief Operating Officer | 58 | 01/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Sununu
BRD | Director/Board Member | 61 | 01/04/2009 |
Michael Mahoney
CHM | Chairman | 61 | 03/05/2016 |
Edward Ludwig
BRD | Director/Board Member | 74 | 01/03/2014 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.34% | 1.75% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.76% | -18.45% | -27.53% | +58.60% | 113B | |
| +0.09% | -6.18% | -5.01% | -6.91% | 204B | |
| +2.48% | -3.19% | -16.27% | +92.90% | 173B | |
| +0.40% | -1.04% | +4.76% | -18.57% | 153B | |
| -2.82% | -1.83% | -26.36% | -22.47% | 54.57B | |
| +0.78% | -3.26% | +11.88% | -1.66% | 45.68B | |
| +1.72% | +5.16% | +14.64% | +21.02% | 39.57B | |
| -2.02% | +2.13% | -7.98% | +12.59% | 36.76B | |
| -0.05% | -3.19% | -10.76% | -16.13% | 36.65B | |
| -1.36% | +0.12% | -24.56% | -40.26% | 33.03B | |
| Average | -0.25% | -3.20% | -8.72% | +7.91% | 88.98B | |
| Weighted average by Cap. | +0.16% | -5.27% | -9.04% | +18.60% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 20.07B 16.99B 15.6B 14.77B 27.44B 1,818B 28.57B 181B 71.62B 874B 75.27B 73.72B 3,163B | 22.29B 18.87B 17.32B 16.4B 30.47B 2,018B 31.73B 201B 79.52B 970B 83.58B 81.86B 3,512B |
| Net income | 3.01B 2.55B 2.34B 2.22B 4.12B 273B 4.29B 27.13B 10.74B 131B 11.29B 11.06B 475B | 3.63B 3.08B 2.82B 2.67B 4.97B 329B 5.17B 32.74B 12.97B 158B 13.63B 13.35B 573B |
| Net Debt | 8.83B 7.47B 6.86B 6.5B 12.07B 799B 12.57B 79.54B 31.5B 384B 33.11B 32.43B 1,391B | 5.7B 4.82B 4.43B 4.19B 7.79B 516B 8.11B 51.33B 20.33B 248B 21.36B 20.92B 898B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 76.27 $ | -1.76% | 34,885,737 |
| 05/02/26 | 77.64 $ | +2.83% | 38,316,880 |
| 04/02/26 | 75.50 $ | -17.59% | 78,234,469 |
| 03/02/26 | 91.62 $ | -0.27% | 20,357,382 |
| 02/02/26 | 91.87 $ | -1.77% | 15,424,100 |
Delayed Quote Nyse, February 07, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition